Intended for healthcare professionals

Clinical Review Lesson of the week

Colchicine in acute gout

BMJ 2003; 327 doi: (Published 27 November 2003) Cite this as: BMJ 2003;327:1275
  1. Ian Morris, consultant rheumatologist (ian.morris{at},
  2. George Varughese, senior house officer1,
  3. Peter Mattingly, consultant rheumatologist1
  1. 1Department of Rheumatology, Kettering General Hospital, Kettering, Northamptonshire NN16 8UZ
  1. Correspondence to: I Morris
  • Accepted 5 June 2003


We describe three histories of patients with gout who were treated with doses of colchicine as advised by the British National Formulary(BNF)–that is, 1 mg initially followed by 500 μg every 2-3 hours until relief of pain is obtained or vomiting or diarrhoea occurs or until a total dose of 6 mg has been reached; the course should not be repeated within three days.1 All three patients developed nausea or diarrhoea with this regimen. We consider that an alternative low dose schedule should be used to avoid such adverse events.

Case reports

Case 1–A 91 year old woman with a history of ischaemic heart disease and non-insulin dependent diabetes developed an ulcer over the right first metatarsophalangeal joint, which was discharging a white toothpaste-like material containing urate crystals. She was given 1 mg colchicine and then 500 μg every three hours, but she developed diarrhoea, and colchicine was stopped. After three days, the toe was still painful, and the course was repeated. She developed severe diarrhoea again and became dehydrated and unwell. We rehydrated her intravenously and gave her meloxicam. After the first few days we started her on colchicine 500 μg daily. She tolerated this well and it helped with pain relief.

Case 2–An 88 year old woman with a history of ischaemic heart disease, atrial fibrillation, congestive cardiac failure, chronic renal failure, hypertension, and osteoarthritis was admitted with pain in her right knee. Investigations led to a diagnosis of acute gouty monoarthritis (serum urea 27.1 mmol/l, serum creatinine 236 μmol/l, and serum uric acid 920 mmol/l). She was given 1 mg colchicine and then 500 μg every eight hours (a reduced dose because the BNF advises caution with renal and cardiac impairment). Within two days she developed nausea and vomiting. We stopped colchicine for 24 hours and then resumed with 500 μg twice a day. This improved her right knee pain without further nausea.

Case 3–A 56 year old man in general good health with recurrent acute gout found that non-steroidal anti-inflammatory drugs were ineffective and productive of severe indigestion; therefore he was given 1 mg colchicine and 500 μg every three hours for acute attacks. With this regimen, he had diarrhoea and sickness, and the acute attacks of gout continued. We reduced colchicine to 500 μg two or three times a day, which was effective without adverse event.


The current BNF recommends a regimen for colchicine which is unchanged since the 1966 edition. The same regimen was also expressed in grains in Hollander's Textbook of Rheumatology, 1960. (The BNF is an authoritative guide on drugs and their use. In a recent survey of general medical staff in our hospital, of the 17 respondents, 12 said they would follow the BNF's advice, three gave no indication as to what dose they would use, one suggested an improbably large dose, and one would never use colchicine.)

The BNF states that colchicine is probably at least as effective as a non-steroidal anti-inflammatory drug in an acute attack of gout (although to our knowledge only one double blind placebo controlled study has been done with colchicine in gout,2 and none has been done for NSAIDs and gout). The BNF also states that colchicine does not induce fluid retention and can therefore be used in heart failure, and it can be given to patients on anticoagulants. Thus the non-specialist is encouraged to use colchicine, especially when other treatments such as non-steroidal anti-inflammatory drugs or sometimes steroids (whether local or systematic) are inappropriate or ineffective. The BNF cautions about gastrointestinal disease, cardiac, hepatic, and renal insufficiency, but the only contraindication noted is pregnancy.

Although non-specialists are likely to prescribe the regimen as given, many rheumatologists have never used such high doses because they were trained to use low dosages even in acute gout. Low dosages were first advocated for the long term treatment of gout in the 1930s and are now used as prophylaxis while treating with allopurinol or uricosuric agents (using a lower dosage of colchicine during induction of urate reducing drugs is already mentioned in the BNF).3 Even though lower doses of colchicine for acute gout were advocated in the ABC of Rheumatology in 1995,4 a recent editorial in the BMJ still advocated the traditional high dose regimen.5

Empirical studies by rheumatologists over many years have shown the effectiveness of low doses of colchicine for acute gout without adverse events. We do not advocate an increase in the use of colchicine because non-steroidal anti-inflammatory drugs are usually highly effective, but we think lower dosages of colchicine should be publicised as being effective and much less likely to produce side effects than traditional high dose regimens. The side effects of nausea, vomiting, or diarrhoea are particularly difficult to endure in patients who are in pain, incapacitated, and immobile from acute gouty arthritis.

We suggest that in acute gouty arthritis colchicine should be used at a dose of 500 μg three times a day or less frequently, especially in those with renal impairment. In the absence of any other recent studies the BNF should provide this information which would benefit many patients.

In acute gout, lower doses of colchicine are effective yet less toxic than traditional regimens


Contributors: PM and IM were involved in managing the patients and thought it worth while promoting the use of lower doses of colchicine. GV wrote the case histories and did the staff survey. All authors wrote the article. IM is guarantor.


  • Funding None.

  • Competing interests None declared.


View Abstract